Cergutuzumab amunaleukin
- Generic Name
- Cergutuzumab amunaleukin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1509916-03-3
- Unique Ingredient Identifier
- 48FCG62C25
- Background
Cergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT02350673
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇺🇸SCRI-Tennessee Oncology, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath